Tommaso A. Dragani

{{Infobox person

| name = Tommaso A. Dragani

| image =

| birth_date =

| birth_place = Ortona, Italy

| death_date =

| death_place =

| alma_mater = University of Bologna (Graduation with honors)
University of Milano (Master in Medical Statistics and Statistical Methods in Epidemiology)

| occupation = Cancer researcher, Genetic epidemiologist, toxicologist

| spouse =

| children =

}}

Tommaso A. Dragani is an Italian genetic epidemiologist whose research is focused on understanding the genetic control of complex phenotypes.Cancer Res. 1993;53:209-11Nat Genet. 1993;3:132-6Nat Genet.1996;12:455-7Oncogene. 2000;19:5324-8PLoS Genet. 2014;10:e1004307Cancer Lett. 2016;375:221-230

Results from his studies allowed the chromosomal mapping of quantitative trait loci (QTLs) modulating the genetic predisposition to liver, lung and skin tumorigenesis, in animal models.Cancer Res. 1993;53:209-11Nat Genet. 1993;3:132-6Nat Genet.1996;12:455-7Oncogene. 2000;19:5324-8PLoS Genet. 2014;10:e1004307Cancer Lett. 2016;375:221-230 His population-based studies resulted in the identification of genetic polymorphisms associated with the risk and prognosis of lung cancer. He contributed to discovering the mechanism underlying the association between polymorphisms in nicotinic acetylcholine receptor subunit genes on chromosome 15 and the risks of lung cancer and nicotine dependence.J Natl Cancer Inst. 2010;102:1366-70Carcinogenesis. 2013;34:1281-5 He contributed with a genome-wide study to the pharmacogenomics of pain relief in response to opioid therapy for cancer pain.Clin Cancer Res. 2011;17:4581-7

Biography

Dragani was born in Ortona, Italy, and studied pharmacy at the University of Bologna where he received and MPharm degree in 1977. He then joined the {{ill|National Cancer Institute in Milan|it|Fondazione IRCCS Istituto nazionale dei tumori}} as a researcher.{{citation needed|date=April 2020}}

From June 1984 to June 1985, he was visiting scientist at the laboratory of Bernard Weinstein, Columbia University, and from September 1996 to February 1997 he was visiting scientist at the {{ill|National Cancer Center Japan|jp|国立がん研究センター}}, working with Minako Nagao.{{citation needed|date=April 2020}}

In 1998, Dragani was appointed Director of the Genetic Epidemiology and Pharmacogenomics Research Unit at the National Cancer Institute in Milan. In 2007 he achieved a Masters in Medical Statistics and Statistical Methods in Epidemiology by the University of Milan.{{citation needed|date=April 2020}}

Achievements

Tommaso A. Dragani identified genetic loci that influence the hereditary predisposition to liver cancer (Cancer Res. 1993;53:209-11Cancer Res. 1993;53:209-11), lung cancer (Nat Genet. 1993;3:132-6;Nat Genet. 1993;3:132-6 Nat Genet.1996;12:455-7Nat Genet.1996;12:455-7), and skin cancer (Oncogene. 2000;19:5324-8Oncogene. 2000;19:5324-8). He characterized genes involved in the hereditary predisposition to lung cancer in mice and identified genetic loci that modulate the expression of these genes (PLoS Genet. 2014;10:e1004307;PLoS Genet. 2014;10:e1004307 Cancer Lett. 2016;375:221-230Cancer Lett. 2016;375:221-230).

He conducted a genome-wide association study (GWAS) between genetic polymorphisms and lung cancer (J Clin Oncol. 2006;24:1672-8J Clin Oncol. 2006;24:1672-8). He demonstrated that polymorphisms in the CHRNA5 gene promoter modulated the transcription of this gene, and thereby showed that genetic variants affected the risks of lung cancer and nicotine dependence (J Natl Cancer Inst. 2010;102:1366-70;J Natl Cancer Inst. 2010;102:1366-70 Carcinogenesis. 2013;34:1281-5Carcinogenesis. 2013;34:1281-5).

He did a GWAS on pain relief in cancer patients treated with opioids, demonstrating that different genetic loci control the individual response to this therapy (Clin Cancer Res. 2011;17:4581-7Clin Cancer Res. 2011;17:4581-7).

He discovered the tumor-promoting activity of 1,4-bis[2-(3,5-dichloropyridiloxy)]benzene (TCPOBOP), a constitutive androstan receptor agonist ( [12] and he characterized carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).Della Porta G, Dragani TA, Sozzi G. Carcinogenic effects of infantile and long-term 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment in the mouse. Tumori. 1987;73(2):99–107.

Memberships

Tommaso A. Dragani participated as a member of International Working Groups on cancer research.

In particular, he was Member of six IARC Monographs Working Groups on the Evaluation of Carcinogenic Risks to Humans.World Health Organization International Agency for Research on Cancer, Iarc Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 57. Occupational exposures of hairdressers and barbers and personal use of hair colourants; some hair dyes, cosmetic colourants, industrial dyestuffs, and aromatic amines, LYONWorld Health Organization International Agency for Research on Cancer, Iarc Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 59. Hepatitis viruses, LYONWorld Health Organization International Agency for Research on Cancer, Iarc Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 60. Some industrial chemicals, LYONWorld Health Organization International Agency for Research on Cancer, Iarc Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 71. Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide, LYONWorld Health Organization International Agency for Research on Cancer, Iarc Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 76. Some antiviral and antineoplastic drugs, and other pharmaceutical agents, LYONWorld Health Organization International Agency for Research on Cancer, Iarc Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 77. Some industrial chemicals, LYON

He, also, served as a Member of the International Lung Cancer Consortium (ILCCO),International Lung Cancer Consortium (ILCCO) an organization that aims to share data from ongoing lung cancer case-control and cohort studies, in particular regarding genetic association studies. The overall objectives are to reduce duplication of research effort, replicate novel findings, and afford substantial cost savings through large collaborative efforts.